An amino acid substitution in HCV core antigen limits its use as a reliable measure of HCV infection compared with HCV RNA

PLoS One. 2023 Jun 29;18(6):e0287694. doi: 10.1371/journal.pone.0287694. eCollection 2023.

Abstract

Hepatitis C virus (HCV) is a viral pathogen that causes chronic hepatitis, which can lead to cirrhosis and hepatocellular carcinoma. Detection of HCV RNA is the standard method used to diagnose the disease and monitor antiviral treatment. A quantification assay for the HCV core antigen (HCVcAg) has been proposed as a simplified alternative to the HCV RNA test for predicting active HCV infection, with the aim of achieving the global goal of eliminating hepatitis. The objective of this study was to determine the correlation between HCV RNA and HCVcAg, as well as the impact of amino acid sequence heterogeneity on HCVcAg quantification. Our findings demonstrated a strong positive correlation between HCV RNA and HCVcAg across all HCV genotypes (1a, 1b, 3a, and 6), with correlation coefficients ranging from 0.88 to 0.96 (p < 0.001). However, in some cases, samples with genotypes 3a and 6 exhibited lower HCVcAg levels than expected based on the corresponding HCV RNA values. Upon the core amino acid sequence alignment, it was observed that samples exhibiting low core antigen levels had an amino acid substitution at position 49, where threonine was replaced by either alanine or valine. Core mutation at this position may correlate with one of the epitope regions recognized by anti-HCV monoclonal antibodies. The present findings suggest that the utilization of HCVcAg as a standalone marker for HCV RNA might not provide adequate sensitivity for the detection of HCV infection, especially in cases where there are variations in the amino acid sequence of the core region and a low viral load of HCV RNA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Substitution
  • Hepacivirus / genetics
  • Hepatitis C Antibodies
  • Hepatitis C Antigens / genetics
  • Hepatitis C* / diagnosis
  • Humans
  • Liver Neoplasms*
  • RNA

Substances

  • Hepatitis C Antigens
  • Hepatitis C Antibodies
  • RNA

Grants and funding

“This study was part of a viral hepatitis elimination project in Thailand and was supported by the National Research Council of Thailand, Thailand Grand Challenge Fund (RES_64_058_30_020), Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript”